These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34915056)

  • 1. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifileucel (Amtagvi): A cellular therapy for melanoma.
    Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651
    [No Abstract]   [Full Text] [Related]  

  • 5. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma.
    Wang H; Tran TT; Duong KT; Nguyen T; Le UM
    Mol Pharm; 2022 Dec; 19(12):4487-4505. PubMed ID: 36305753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Changes in Systemic Therapy for Advanced Melanoma.
    Thompson JA
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):638-40. PubMed ID: 27226502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
    Li SN; Wan X; Peng LB; Li YM; Li JH
    BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
    Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P
    Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
    Miller DM; Trowbridge RM; Desai A; Drews RE
    J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
    Gil-Rojas Y; Lasalvia P; Hernández F; Castañeda-Cardona C; Castrillón-Correa J; Herrera D; Rosselli D
    Value Health Reg Issues; 2021 Dec; 26():182-190. PubMed ID: 34673349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opdualag for metastatic melanoma.
    Med Lett Drugs Ther; 2023 Jan; 65(1668):e19-e20. PubMed ID: 36651796
    [No Abstract]   [Full Text] [Related]  

  • 20. [Malignant head and neck melanoma: Part 2: Therapy].
    Pföhler C; Vogt T; Müller CS
    HNO; 2015 Aug; 63(8):593-602; quiz 603-4. PubMed ID: 26219523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.